Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

被引：25
|
作者：
Schjesvold, Fredrik [1 ,2 ]
Richardson, Paul G. [3 ]
Facon, Thierry [4 ]
Alegre, Adrian [5 ,6 ]
Spencer, Andrew [7 ]
Jurczyszyn, Artur [8 ]
Sunami, Kazutaka [9 ]
Frenzel, Laurent [10 ]
Min, Chang-Ki [11 ,12 ]
Guillonneau, Sophie [13 ]
Lin, Peggy L. [14 ]
Le-Guennec, Solenn [15 ]
Campana, Frank [16 ]
van de Velde, Helgi [16 ]
Bensfia, Samira [14 ]
Bringhen, Sara [17 ]
机构：
[1] Oslo Univ Hosp, Oslo Myeloma Ctr, Oslo, Norway
[2] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Lille Univ Hosp, Lille, France
[5] Hosp Univ La Princesa, Madrid, Spain
[6] Hosp Quironsalud, Madrid, Spain
[7] Monash Univ, Alfred Hlth, Dept Clin Hematol, Melbourne, Vic, Australia
[8] Jagiellonian Univ, Coll Med, Dept Hematol, Krakow, Poland
[9] Natl Hosp Org Okayama Med Ctr, Dept Hematol, Okayama, Japan
[10] Hop Necker Enfants Malad, Paris, France
[11] Catholic Hematol Hosp, Dept Hematol, Seoul, South Korea
[12] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Leukemia Res Inst, Seoul, South Korea
[13] Sanofi CMO, Chilly Mazarin, France
[14] Sanofi Global Oncol, Cambridge, MA USA
[15] Sanofi R&D, Vitry Sur Seine, France
[16] Sanofi R&D, Cambridge, MA USA
[17] Univ Torino, Azienda Osped Univ Citta Salute & Sci Torino, Myeloma Unit, Div Hematol, Turin, Italy
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 04期
关键词：
SAR650984;
D O I：
10.3324/haematol.2020.253450
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1182 / 1187
页数：6
相关论文
共 50 条
  • [41] Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients
    Morio Matsumoto
    Kenshi Suzuki
    Junya Kuroda
    Masafumi Taniwaki
    Kazutaka Sunami
    Hiroshi Kosugi
    Kiyoshi Ando
    Dai Maruyama
    Kensei Tobinai
    Uma Kher
    Mohammed Farooqui
    Jason Liao
    Patricia Marinello
    Kenji Matsuda
    Yasuhiro Koh
    Takashi Shimamoto
    Shinsuke Iida
    International Journal of Hematology, 2021, 113 : 777 - 784
  • [42] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    BLOOD, 2017, 130 (08) : 974 - 981
  • [43] Efficacy Outcomes of Isatuximab with Pomalidomide and Dexamethasone Are Comparable to (ICARIA-MM) Trial Data: Initial Results of a UK-Wide Real-World Study of Relapsed Myeloma Patients
    Djebbari, Faouzi
    Vallance, Grant
    Basker, Nanda
    Panitsas, Fotios
    Rampotas, Alexandros
    Sangha, Gina
    Salhan, Beena
    Karim, Farheen
    Al-kaisi, Firas
    Gudger, Amy
    Ngu, Loretta
    Poynton, Matt
    Lam, Ho Pui Jeff
    Morgan, Lowri
    Yang, Laura
    Young, Jennifer
    Walker, Mairi
    Tsagkaraki, Ismini
    Anderson, Laura
    Chauhan, Saleena Rani
    Maddams, Rebecca
    Stirton, Lesley
    Triantafillou, Margarita
    Prideaux, Steve
    Obeidalla, Abubaker
    Bygrave, Ceri
    Basu, Supratik
    Ramasamy, Karthik
    BLOOD, 2021, 138 : 1963 - +
  • [44] Isatuximab plus Carfilzomib and Dexamethasone in East Asian patients with relapsed Multiple Myeloma: IKEMA subgroup analysis
    Kim, Kihyun
    Min, Chang-Ki
    Koh, Youngil
    Ishizawa, Kenichi
    Kim, Sung-Hyun
    Ito, Shigeki
    Tanaka, Junji
    Uchiyama, Michihiro
    Kawano, Yawara
    Kim, Jin Seok
    Moreau, Philippe
    Martin, Thomas
    Dong, Yvonne
    Risse, Marie-Laure
    Suzuki, Kenshi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S146 - S147
  • [45] A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mikhael, J.
    Richardson, P.
    Usmani, S.
    Raje, N.
    Bensinger, W.
    Kanagavel, D.
    Gao, L.
    Ziti-ljajic, S.
    Anderson, K.
    HAEMATOLOGICA, 2017, 102 : 168 - 168
  • [46] Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis
    Kihyun Kim
    Chang-Ki Min
    Youngil Koh
    Kenichi Ishizawa
    Sung-Hyun Kim
    Shigeki Ito
    Junji Tanaka
    Michihiro Uchiyama
    Yawara Kawano
    Jin Seok Kim
    Philippe Moreau
    Thomas Martin
    Yvonne Dong
    Marie-Laure Risse
    Kenshi Suzuki
    International Journal of Hematology, 2022, 116 : 553 - 562
  • [47] Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis
    Kim, Kihyun
    Min, Chang-Ki
    Koh, Youngil
    Ishizawa, Kenichi
    Kim, Sung-Hyun
    Ito, Shigeki
    Tanaka, Junji
    Uchiyama, Michihiro
    Kawano, Yawara
    Kim, Jin Seok
    Moreau, Philippe
    Martin, Thomas
    Dong, Yvonne
    Risse, Marie-Laure
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (04) : 553 - 562
  • [48] OPTIMISMM Japanese Subgroup Analysis: Pomalidomide, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Matsue, Kosei
    Sunami, Kazutaka
    Suzuki, Kenshi
    Takezako, Naoki
    Shinagawa, Atsushi
    Sakurai, Sanae
    Tamakoshi, Hiromi
    Biyukov, Tsvetan
    Peluso, Teresa
    Richardson, Paul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E270 - E271
  • [49] Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status
    Decaux, Olivier
    Lafore, Radhia
    Iaquinta, Daniel
    Tekle, Christina
    Leleu, Xavier
    BLOOD, 2022, 140 : 10969 - 10970
  • [50] Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
    De Novellis, Danilo
    Derudas, Daniele
    Vincelli, Donatella
    Fontana, Raffaele
    Della Pepa, Roberta
    Palmieri, Salvatore
    Accardi, Fabrizio
    Rotondo, Francesco
    Morelli, Emanuela
    Gigliotta, Emilia
    Roccotelli, Daniela
    Marano, Luana
    Barone, Maria Lucia
    Cetani, Giusy
    Esposito, Daniela
    Lazzaro, Antonio
    Delle Cave, Giuseppe
    Serio, Bianca
    Morini, Denise
    Porrazzo, Marika
    Urciuoli, Eleonora
    Masucci, Chiara
    Fanelli, Fulvia
    Rizzo, Michela
    Arcamone, Manuela
    Trastulli, Fabio
    Rocco, Stefano
    Leone, Aldo
    Bianco, Rosario
    Salvatore, Flavia
    Idato, Aurora
    Sicari, Maria
    Tosi, Patrizia
    Rascato, Maria Gabriella
    Di Perna, Maria
    Falcone, Antonietta Pia
    Morello, Lucia
    Carlisi, Melania
    Svanera, Gino
    Annunziata, Mario
    Frigeri, Ferdinando
    Califano, Catello
    Carella, Angelo Michele
    Marcacci, Gianpaolo
    Pane, Fabrizio
    Risitano, Antonio Maria
    Giudice, Valentina
    Botta, Ciro
    Selleri, Carmine
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (01) : 105 - 114
12345